Ozempic vs Insulin: Product Attributes Comparison for Diabetes Care
For diabetes care professionals evaluating **Ozempic vs Insulin**, this comparison examines key product attributes. **Ozempic** (semaglutide) is a GLP-1 receptor agonist, while **insulin** (various analogs) directly replaces endogenous hormone. Market trends show rising preference for GLP-1s due to weight loss benefits and once-weekly dosing. **Brand comparison**: Ozempic (Novo Nordisk) offers superior glycemic control with lower hypoglycemia risk; insulin requires precise titration. **Advantages**: Ozempic supports cardiovascular health; insulin provides rapid, flexible correction. **Parameters**: Ozempic’s half-life (~7 days) vs insulin’s hours. **Usage**: Ozempic for type 2 diabetes; insulin for type 1 or advanced type 2. **Qualification**: Prescription-only; patient selection critical. **Procurement tips**: Verify pharmacy licensing, compare bulk pricing, and ensure cold-chain compliance for insulin. Prioritize patient-specific needs when selecting between these therapies.